Tayyebeh M Nazeran
Overview
Explore the profile of Tayyebeh M Nazeran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orr N, Albert A, Liu Y, Lum A, Hong J, Ionescu C, et al.
J Pathol Clin Res
. 2023 Mar;
9(4):302-312.
PMID: 36977195
The clinical phenotype of somatic mutations in endometriosis is unknown. The objective was to determine whether somatic KRAS mutations were associated with greater disease burden in endometriosis (i.e. more severe...
2.
Praetorius T, Leonova A, Lac V, Senz J, Tessier-Cloutier B, Nazeran T, et al.
Fertil Steril
. 2022 Jun;
118(3):524-534.
PMID: 35715244
Objective: To investigate the heterogeneity of somatic cancer-driver mutations within patients and across endometriosis types. Design: A single-center cohort, retrospective study. Setting: Tertiary specialist-care center at a university hospital. Patient(s):...
3.
Heinze K, Nazeran T, Lee S, Kramer P, Cairns E, Chiu D, et al.
J Pathol
. 2021 Dec;
256(4):388-401.
PMID: 34897700
ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are...
4.
Kramer P, Talhouk A, Brett M, Chiu D, Cairns E, Scheunhage D, et al.
Clin Cancer Res
. 2020 Aug;
26(20):5400-5410.
PMID: 32737030
Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared with other ovarian carcinomas. Nonetheless, current patient treatment continues to follow a "one-size-fits-all" approach. Even though...
5.
Martins F, Couturier D, Paterson A, Karnezis A, Chow C, Nazeran T, et al.
Br J Cancer
. 2020 Jun;
123(5):793-802.
PMID: 32555365
Background: PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN...
6.
Talhouk A, George J, Wang C, Budden T, Tan T, Chiu D, et al.
Clin Cancer Res
. 2020 Jun;
26(20):5411-5423.
PMID: 32554541
Purpose: Gene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been...
7.
Cybulska P, Da Cruz Paula A, Tseng J, Leitao Jr M, Bashashati A, Huntsman D, et al.
Gynecol Oncol
. 2019 Jul;
154(3):516-523.
PMID: 31340883
Objective: Endometrioid ovarian carcinomas (EOCs) comprise 5-10% of all ovarian cancers and commonly co-occur with synchronous endometrioid endometrial cancer (EEC). We sought to examine the molecular characteristics of pure EOCs...
8.
Lac V, Nazeran T, Tessier-Cloutier B, Aguirre-Hernandez R, Albert A, Lum A, et al.
J Pathol
. 2019 Jun;
249(2):173-181.
PMID: 31187483
The advent of next generation sequencing has vastly improved the resolution of mutation detection, thereby both increasing the resolution of the analysis of cancer tissues and shining light on the...
9.
Peres L, Cushing-Haugen K, Anglesio M, Wicklund K, Bentley R, Berchuck A, et al.
Gynecol Oncol
. 2018 Aug;
151(1):53-60.
PMID: 30121132
Objective: Major changes in the classification of ovarian carcinoma histotypes occurred over the last two decades, resulting in the current 2014 World Health Organization (WHO) diagnostic criteria that recognize five...
10.
Yanagida S, Anglesio M, Nazeran T, Lum A, Inoue M, Iida Y, et al.
PLoS One
. 2017 Jun;
12(6):e0178989.
PMID: 28594898
Background: Adult-type granulosa cell tumors of the ovary (aGCTs) are rare tumors that represent 2-5% of ovarian malignancies. The prognosis of this tumor is favorable, and it is characterized by...